A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice

Journal of Immunology

Volumn 186, Issue 4, 2011, Pages 2454-2461

  Fukuyama, Yoshiko ^a   King, Janice D ^b   Kataoka, Kosuke ^c   Kobayashi, Ryoki ^a   Gilbert, Rebekah S ^b   Hollingshead, Susan K ^b   Briles, David E ^b   Fujihashi, Kohtaro ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CD11B ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; CPG OLIGODEOXYNUCLEOTIDE; FLT3 LIGAND; IMMUNOGLOBULIN A ANTIBODY; PNEUMOCOCCAL SURFACE PROTEIN A; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ALLOIMMUNITY; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; CD4+ T LYMPHOCYTE; CERVICAL LYMPH NODE; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SPLEEN; STREPTOCOCCUS PNEUMONIAE; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; AGING; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CELLS, CULTURED; CPG ISLANDS; DNA, COMPLEMENTARY; DRUG COMBINATIONS; HUMANS; IMMUNOGLOBULIN A, SECRETORY; MEMBRANE PROTEINS; MICE; NASAL MUCOSA; OLIGODEOXYRIBONUCLEOTIDES; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 79951849275     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002837     Document Type: Article

References (48)

1. Murray, C. J., and A. D. Lopez. 1997. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349: 1269-1276.
2. Janssens, J. P., and K. H. Krause. 2004. Pneumonia in the very old. Lancet Infect. Dis. 4: 112-124.
3. Lue, C., A. Tarkowski, and J. Mestecky. 1988. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory antipneumococcal antibodies. J. Immunol. 140: 3793-3800.
4. Tarkowski, A., C. Lue, Z. Moldoveanu, H. Kiyono, J. R. McGhee, and J. Mestecky. 1990. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses. J. Immunol. 144: 3770-3778. (Pubitemid 20171184)
5. Schenkein, J. G., M. H. Nahm, and M. T. Dransfield. 2008. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest 133: 767-774.
6. Shapiro, E. D., A. T. Berg, R. Austrian, D. Schroeder, V. Parcells, A. Margolis, R. K. Adair, and J. D. Clemens. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325: 1453-1460.
7. Romero-Steiner, S., D. M. Musher, M. S. Cetron, L. B. Pais, J. E. Groover, A. E. Fiore, B. D. Plikaytis, and G. M. Carlone. 1999. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29: 281-288.
8. Rubins, J. B., M. Alter, J. Loch, and E. N. Janoff. 1999. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect. Immun. 67: 5979-5984.
9. Rubins, J. B., A. K. Puri, J. Loch, D. Charboneau, R. MacDonald, N. Opstad, and E. N. Janoff. 1998. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J. Infect. Dis. 178: 431-440.
10. Arulanandam, B. P., J. M. Lynch, D. E. Briles, S. K. Hollingshead, and D. W. Metzger. 2001. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun. 69: 6718-6724.
11. Briles, D. E., S. K. Hollingshead, J. C. Paton, E. W. Ades, L. Novak, F. W. van Ginkel, and W. H. Benjamin, Jr. 2003. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J. Infect. Dis. 188: 339-348.
12. Ogunniyi, A. D., M. Grabowicz, D. E. Briles, J. Cook, and J. C. Paton. 2007. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect. Immun. 75: 350-357.
13. Yamamoto, M., D. E. Briles, S. Yamamoto, M. Ohmura, H. Kiyono, and J. R. McGhee. 1998. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 161: 4115-4121.
14. + T cells in nasopharyngeal-associated lymphoreticular tissue. J. Immunol. 170: 1754-1762.
15. Koga, T., J. R. McGhee, H. Kato, R. Kato, H. Kiyono, and K. Fujihashi. 2000. Evidence for early aging in the mucosal immune system. J. Immunol. 165: 5352-5359.
16. Fujihashi, K., and H. Kiyono. 2009. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol. 30: 334-343.
17. Fukuiwa, T., S. Sekine, R. Kobayashi, H. Suzuki, K. Kataoka, R. S. Gilbert, Y. Kurono, P. N. Boyaka, A. M. Krieg, J. R. McGhee, and K. Fujihashi. 2008. A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine 26: 4849-4859.
18. Boyaka, P. N., A. Tafaro, R. Fischer, S. H. Leppla, K. Fujihashi, and J. R. McGhee. 2003. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170: 5636-5643.
19. + dendritic cells for enhanced mucosal immunity. J. Immunol. 172: 3612-3619.
20. McCluskie, M. J., and H. L. Davis. 1999. CpG DNA as mucosal adjuvant. Vaccine 18: 231-237.
21. Briles, D. E., E. Ades, J. C. Paton, J. S. Sampson, G. M. Carlone, R. C. Huebner, A. Virolainen, E. Swiatlo, and S. K. Hollingshead. 2000. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun. 68: 796-800.
22. McDaniel, L. S., B. A. Ralph, D. O. McDaniel, and D. E. Briles. 1994. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb. Pathog. 17: 323-337.
23. Yother, J., and D. E. Briles. 1992. Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J. Bacteriol. 174: 601-609.
24. Fukuyama, Y., J. D. King, K. Kataoka, R. Kobayashi, R. S. Gilbert, K. Oishi, S. K. Hollingshead, D. E. Briles, and K. Fujihashi. 2010. Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J. Immunol. 185: 1755-1762.
25. Fujihashi, K., T. Dohi, P. D. Rennert, M. Yamamoto, T. Koga, H. Kiyono, and J. R. McGhee. 2001. Peyer's patches are required for oral tolerance to proteins. Proc. Natl. Acad. Sci. USA 98: 3310-3315.
26. Hagiwara, Y., Y. I. Kawamura, K. Kataoka, B. Rahima, R. J. Jackson, K. Komase, T. Dohi, P. N. Boyaka, Y. Takeda, H. Kiyono, et al. 2006. A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J. Immunol. 177: 3045-3054. (Pubitemid 44277821)
27. Sekine, S., K. Kataoka, Y. Fukuyama, Y. Adachi, J. Davydova, M. Yamamoto, R. Kobayashi, K. Fujihashi, H. Suzuki, D. T. Curiel, et al. 2008. A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. J. Immunol. 180: 8126-8134.
28. Briles, D. E., M. J. Crain, B. M. Gray, C. Forman, and J. Yother. 1992. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect. Immun. 60: 111-116.
29. Brazolot Millan, C. L., R. Weeratna, A. M. Krieg, C. A. Siegrist, and H. L. Davis. 1998. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA 95: 15553-15558.
30. Eastcott, J. W., C. J. Holmberg, F. E. Dewhirst, T. R. Esch, D. J. Smith, and M. A. Taubman. 2001. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 19: 1636-1642.
31. McCluskie, M. J., and H. L. Davis. 1998. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161: 4463-4466.
32. Moldoveanu, Z., L. Love-Homan, W. Q. Huang, and A. M. Krieg. 1998. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16: 1216-1224.
33. Chu, R. S., T. McCool, N. S. Greenspan, J. R. Schreiber, and C. V. Harding. 2000. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect. Immun. 68: 1450-1456.
34. Maletto, B. A., A. S. Rópolo, M. V. Liscovsky, D. O. Alignani, M. Glocker, and M. C. Pistoresi-Palencia. 2005. CpG oligodeoxinucleotides functions as an effective adjuvant in aged BALB/c mice. Clin. Immunol. 117: 251-261.
35. Manning, B. M., E. Y. Enioutina, D. M. Visic, A. D. Knudson, and R. A. Daynes. 2001. CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice. Exp. Gerontol. 37: 107-126.
36. Qin, W., J. Jiang, Q. Chen, N. Yang, Y. Wang, X. Wei, and R. Ou. 2004. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice. Cell. Mol. Immunol. 1: 148-152.
37. +-T-cell priming to young adult levels. Infect. Immun. 74: 2177-2186.
38. Alignani, D., B. Maletto, M. Liscovsky, A. Rópolo, G. Morón, and M. C. Pistoresi-Palencia. 2005. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J. Leukoc. Biol. 77: 898-905.
39. Haynes, L., S. M. Eaton, E. M. Burns, M. Rincon, and S. L. Swain. 2004. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J. Immunol. 172: 5194-5199.
40. Moretto, M. M., E. M. Lawlor, and I. A. Khan. 2008. Aging mice exhibit a functional defect in mucosal dendritic cell response against an intracellular pathogen. J. Immunol. 181: 7977-7984.
41. + T cell help. J. Immunol. 172: 532-539.
42. + T cells. Infect. Immun. 76: 2678-2684.
43. Vasilevsky, S., J. Colino, R. Puliaev, D. H. Canaday, and C. M. Snapper. 2008. Macrophages pulsed with Streptococcus pneumoniae elicit a T cell-dependent antibody response upon transfer into naive mice. J. Immunol. 181: 1787-1797.
44. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
45. Weiner, G. J. 2000. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J. Leukoc. Biol. 68: 455-463.
46. - but not plasmacytoid dendritic cells. J. Exp. Med. 205: 1621-1634.
47. Zhang, T., T. Hashizume, T. Kurita-Ochiai, and M. Yamamoto. 2009. Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. Biochem. Biophys. Res. Commun. 390: 937-941.
48. Takenaka, S., E. Safroneeva, Z. Xing, and J. Gauldie. 2007. Dendritic cells derived from murine colonic mucosa have unique functional and phenotypic characteristics. J. Immunol. 178: 7984-7993. (Pubitemid 46898069)